Entropy Neurodynamics Limited has released a press release.
FY2023 Appendix 4E
Filed with ASX ·
On 6ix: 6ix.com/news/fy2023-appendix-4e
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- EX1 early stage success with in house Elastin (ELN) program
- Results of Non-Renounceable Rights Issue
- Exopharm Limited announces Non-Renounceable Pro Rata Rights
- Disclosure Document - Rights Issue Prospectus
- EX1 to Receive $1m from the Issue of Convertible Notes
Later from Entropy Neurodynamics
- Suspension from Quotation
- Further management changes and cost-reductions
- Appendix 4D and Half Year Report for period 31 December 2023
- EX1 signs binding agreement to acquire Tryp Therapeutics
- 2024 General Meeting Letter of Access, Notice and Proxy
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics